Meta Biomed Co., Ltd.

KOSDAQ:A059210 Stock Report

Market Cap: ₩153.4b

Meta Biomed Future Growth

Future criteria checks 4/6

Meta Biomed is forecast to grow earnings and revenue by 24.7% and 16.7% per annum respectively. EPS is expected to grow by 19.7% per annum. Return on equity is forecast to be 18.9% in 3 years.

Key information

24.7%

Earnings growth rate

19.72%

EPS growth rate

Medical Equipment earnings growth38.2%
Revenue growth rate16.7%
Future return on equity18.90%
Analyst coverage

Low

Last updated08 Sep 2025

Recent future growth updates

No updates

Recent updates

Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Share Price Is Matching Sentiment Around Its Earnings

Sep 11
Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Share Price Is Matching Sentiment Around Its Earnings

Does Meta Biomed (KOSDAQ:059210) Deserve A Spot On Your Watchlist?

May 28
Does Meta Biomed (KOSDAQ:059210) Deserve A Spot On Your Watchlist?

Meta Biomed's (KOSDAQ:059210) Returns On Capital Are Heading Higher

May 08
Meta Biomed's (KOSDAQ:059210) Returns On Capital Are Heading Higher

Even With A 31% Surge, Cautious Investors Are Not Rewarding Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Performance Completely

May 08
Even With A 31% Surge, Cautious Investors Are Not Rewarding Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Performance Completely

There May Be Underlying Issues With The Quality Of Meta Biomed's (KOSDAQ:059210) Earnings

Apr 01
There May Be Underlying Issues With The Quality Of Meta Biomed's (KOSDAQ:059210) Earnings

A Piece Of The Puzzle Missing From Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Share Price

Mar 18
A Piece Of The Puzzle Missing From Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Share Price

Meta Biomed (KOSDAQ:059210) Shareholders Will Want The ROCE Trajectory To Continue

Dec 17
Meta Biomed (KOSDAQ:059210) Shareholders Will Want The ROCE Trajectory To Continue

Earnings Tell The Story For Meta Biomed Co., Ltd. (KOSDAQ:059210) As Its Stock Soars 30%

Feb 26
Earnings Tell The Story For Meta Biomed Co., Ltd. (KOSDAQ:059210) As Its Stock Soars 30%

Here's How We Evaluate Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Dividend

Apr 11
Here's How We Evaluate Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Dividend

Meta Biomed's (KOSDAQ:059210) Stock Price Has Reduced 58% In The Past Five Years

Mar 14
Meta Biomed's (KOSDAQ:059210) Stock Price Has Reduced 58% In The Past Five Years

Are Meta Biomed's (KOSDAQ:059210) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are Meta Biomed's (KOSDAQ:059210) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Can Meta Biomed (KOSDAQ:059210) Continue To Grow Its Returns On Capital?

Feb 03
Can Meta Biomed (KOSDAQ:059210) Continue To Grow Its Returns On Capital?

Is Meta Biomed (KOSDAQ:059210) A Risky Investment?

Jan 13
Is Meta Biomed (KOSDAQ:059210) A Risky Investment?

Here's Why I Think Meta Biomed (KOSDAQ:059210) Is An Interesting Stock

Dec 26
Here's Why I Think Meta Biomed (KOSDAQ:059210) Is An Interesting Stock

Meta Biomed (KOSDAQ:059210) Share Prices Have Dropped 22% In The Last Five Years

Dec 08
Meta Biomed (KOSDAQ:059210) Share Prices Have Dropped 22% In The Last Five Years

Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Nov 20
Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Earnings and Revenue Growth Forecasts

KOSDAQ:A059210 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027151,10031,40032,90032,6001
12/31/2026130,10026,90045,90045,6001
12/31/2025110,30019,10035,50041,5001
6/30/202599,38117,5189,94220,422N/A
3/31/202599,23422,24414,07721,711N/A
12/31/202494,03622,22811,53022,633N/A
9/30/202492,30015,1945,84717,912N/A
6/30/202490,09114,7345,93718,952N/A
3/31/202484,43812,3097515,118N/A
12/31/202383,10110,292-1,27710,217N/A
9/30/202379,5456,787-6,2419,632N/A
6/30/202377,7473,141-10,0707,265N/A
3/31/202375,4284,645-1,9645,952N/A
12/31/202268,9421,874-6,1509,159N/A
9/30/202266,8837,1271,07210,295N/A
6/30/202261,3728,6045,79311,763N/A
3/31/202260,7958,8321,93414,655N/A
12/31/202158,7809,3819,03611,136N/A
9/30/202154,1834,4907,3569,437N/A
6/30/202151,8614,1965,6727,628N/A
3/31/202145,793-1,0931,6383,950N/A
12/31/202044,998-3,0911,8104,862N/A
9/30/202046,8232,0352274,486N/A
6/30/202049,0751,980-4,1911,810N/A
3/31/202056,0345,445-5,2911,411N/A
12/31/201959,3915,527-5,2042,865N/A
9/30/201952,268156-5,1222,248N/A
6/30/201953,19264-28,883-20,263N/A
3/31/201951,518-1,435N/A-1,167N/A
12/31/201852,586953N/A-5,283N/A
9/30/201864,158-4,131N/A-8,173N/A
6/30/201865,530-2,666N/A14,076N/A
3/31/201866,563-2,753N/A-3,204N/A
12/31/201765,341-4,104N/A-249N/A
9/30/201766,531262N/A3,853N/A
6/30/201764,329-635N/A6,498N/A
3/31/201764,383761N/A6,642N/A
12/31/201665,784639N/A5,033N/A
9/30/201665,6392,240N/A4,703N/A
6/30/201667,2361,476N/A2,429N/A
3/31/201668,227322N/A2,279N/A
12/31/201568,592806N/A4,933N/A
9/30/201567,332-2,369N/A2,626N/A
6/30/201566,230-3,088N/A964N/A
3/31/201563,748-4,242N/A962N/A
12/31/201461,365-4,952N/A-296N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A059210's forecast earnings growth (24.7% per year) is above the savings rate (2.9%).

Earnings vs Market: A059210's earnings (24.7% per year) are forecast to grow faster than the KR market (23.7% per year).

High Growth Earnings: A059210's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: A059210's revenue (16.7% per year) is forecast to grow faster than the KR market (7.6% per year).

High Growth Revenue: A059210's revenue (16.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A059210's Return on Equity is forecast to be low in 3 years time (18.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/03 12:42
End of Day Share Price 2025/10/02 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Meta Biomed Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jongsun ParkEugene Investment & Securities Co Ltd.